Growth Metrics

Novavax (NVAX) Convertible Debt (2016 - 2025)

Novavax has reported Convertible Debt over the past 10 years, most recently at $244.2 million for Q4 2025.

  • Quarterly results put Convertible Debt at $244.2 million for Q4 2025, up 43.92% from a year ago — trailing twelve months through Dec 2025 was $244.2 million (up 43.92% YoY), and the annual figure for FY2025 was $244.2 million, up 43.92%.
  • Convertible Debt for Q4 2025 was $244.2 million at Novavax, roughly flat from $243.8 million in the prior quarter.
  • Over the last five years, Convertible Debt for NVAX hit a ceiling of $323.5 million in Q4 2021 and a floor of $166.5 million in Q4 2022.
  • Median Convertible Debt over the past 5 years was $169.7 million (2024), compared with a mean of $213.7 million.
  • Biggest five-year swings in Convertible Debt: crashed 48.54% in 2022 and later surged 44.06% in 2025.
  • Novavax's Convertible Debt stood at $323.5 million in 2021, then plummeted by 48.54% to $166.5 million in 2022, then increased by 0.93% to $168.0 million in 2023, then rose by 0.99% to $169.7 million in 2024, then soared by 43.92% to $244.2 million in 2025.
  • The last three reported values for Convertible Debt were $244.2 million (Q4 2025), $243.8 million (Q3 2025), and $170.6 million (Q2 2025) per Business Quant data.